T-cell immunoglobulin and ITIM domain in cancer immunotherapy : A focus on tumor-infiltrating regulatory T cells
Copyright © 2022 Elsevier Ltd. All rights reserved..
T-cell immunoglobulin and ITIM domain (TIGIT) is a novel type of immune checkpoint. Importantly, immune checkpoint molecules promote cancer progression by various antitumor suppressive mechanisms. TIGIT is an inhibitory receptor expressed on T cells, natural killer cells, and regulatory T cells that was recently attracted attention as a major emerging target for cancer immunotherapy. Regulatory T cells (Tregs) play crucial roles in immune homeostasis. Specifically, tumor-infiltrating Tregs promote cancer progression by restricting antitumor immunity and supporting tumor immune escape. In this review, we summarized the current understanding on TIGIT and tumor-infiltrating Tregs. Here, we reviewed the latest advances in the understanding of mechanisms causing tumor-infiltrating Tregs abundance to optimize Tregs targeted therapy. Collectively, anti-TIGIT targeting Tregs hold great promise for potent cancer target therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:147 |
|---|---|
| Enthalten in: |
Molecular immunology - 147(2022) vom: 02. Juli, Seite 62-70 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tian, Xiaoyan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer immunotherapy |
|---|
| Anmerkungen: |
Date Completed 08.06.2022 Date Revised 13.07.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.molimm.2022.04.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340327677 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340327677 | ||
| 003 | DE-627 | ||
| 005 | 20231226004916.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.molimm.2022.04.014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1134.xml |
| 035 | |a (DE-627)NLM340327677 | ||
| 035 | |a (NLM)35504059 | ||
| 035 | |a (PII)S0161-5890(22)00200-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tian, Xiaoyan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a T-cell immunoglobulin and ITIM domain in cancer immunotherapy |b A focus on tumor-infiltrating regulatory T cells |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.06.2022 | ||
| 500 | |a Date Revised 13.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Ltd. All rights reserved. | ||
| 520 | |a T-cell immunoglobulin and ITIM domain (TIGIT) is a novel type of immune checkpoint. Importantly, immune checkpoint molecules promote cancer progression by various antitumor suppressive mechanisms. TIGIT is an inhibitory receptor expressed on T cells, natural killer cells, and regulatory T cells that was recently attracted attention as a major emerging target for cancer immunotherapy. Regulatory T cells (Tregs) play crucial roles in immune homeostasis. Specifically, tumor-infiltrating Tregs promote cancer progression by restricting antitumor immunity and supporting tumor immune escape. In this review, we summarized the current understanding on TIGIT and tumor-infiltrating Tregs. Here, we reviewed the latest advances in the understanding of mechanisms causing tumor-infiltrating Tregs abundance to optimize Tregs targeted therapy. Collectively, anti-TIGIT targeting Tregs hold great promise for potent cancer target therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Cancer immunotherapy | |
| 650 | 4 | |a Immune checkpoint | |
| 650 | 4 | |a Regulatory T cells | |
| 650 | 4 | |a TIGIT | |
| 650 | 7 | |a Immunoglobulins |2 NLM | |
| 650 | 7 | |a Receptors, Immunologic |2 NLM | |
| 700 | 1 | |a Ning, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Jianqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Shengsong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular immunology |d 1984 |g 147(2022) vom: 02. Juli, Seite 62-70 |w (DE-627)NLM000411434 |x 1872-9142 |7 nnns |
| 773 | 1 | 8 | |g volume:147 |g year:2022 |g day:02 |g month:07 |g pages:62-70 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.molimm.2022.04.014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 147 |j 2022 |b 02 |c 07 |h 62-70 | ||